Penerapan Teknologi General Packet Radio Service Pada Sistem Monitoring Sepeda Motor

General Packet Radio Service (GPRS) merupakan sistem transmisi berbasis paket untuk Global System for Mobile (GSM). Pengembangan sistem keamanan menggunakan GPRS merupakan salah satu bidang yang terus mengalami pembaharuan terutama di negara Indonesia dimana keamanan masih menjadi salah satu fokus dalam perbaikan. Tingkat keamanan kendaraan terutama sepeda motor di Indonesia masih sangat kurang terjamin, hal ini menjadi latar belakang tugas akhir ini dirancang. Alat ini dirancang untuk dapat memberikan informasi tentang keberadaan sepeda motor baik dalam informasi kehilangan maupun informasi posisi kendaraan. Data mengenai informasi kehilangan akan dikirimkan langsung ke Handphone pengguna dengan transmisi GSM dan data mengenai informasi posisi berupa data lintang dan bujur akan dikirimkan menuju database yang dibuat dengan menggunakan MySQl melalui GPRS serta dapat diakses menggunakan website dengan halaman utama menggunakan HyperText Markup Language (HTML) dan koneksi dengan Google Maps API. Peta dasar yang dinamis membuat akurasi yang lebih baik antara data pelacakan dengan penandaan posisi pada peta. Data mengenai posisi akan didapat melalui Global Positioning System (GPS) yang kemudian data tersebut akan diolah menjadi data yang siap dikonversikan pada peta dan dalam bentuk sebuah marker

Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm

We report on a postmenopausal patient with a secondary metastatic apocrine breast cancer successfully treated with low-dose hydrocortisone only following several lines of chemotherapy. The tumor cells in the primary and metastatic lesion exhibited a 'triple-negative' status (estrogen receptor (ER)-, progesterone receptor (PR)-, and human epidermal growth factor receptor 2 (HER2)-negative); the androgen receptor (AR) was strongly expressed. Twenty milligrams of hydrocortisone, a low substitution dose known to suppress adrenal steroid production, twice daily led to a clinical benefit lasting for one year, with symptom control, radiologically stable disease, and steady decrease in CA15.3. Our observation demonstrates that an AR-expressing apocrine breast cancer may respond to androgen deprivation, as an ER-positive breast cancer may benefit from estrogen deprivation. It highlights the importance of further research targeting the AR pathway in apocrine carcinoma, for which androgens represent the sole (known) steroid hormone stimulating tumor growth. Future clinical trials should not only focus on AR inhibitors like enzalutamide, but also on ablative modalities like low-dose hydrocortisone aiming at medical adrenalectomy. This method of androgen deprivation is largely available, cheap, and nearly devoid of toxicity.status: publishe

Withdrawal of exogenous hormones might affect multi-gene signature results in early luminal breast cancer

status: publishe

Treatment decision in early stage ER+ HER2− breast cancer without the 70-gene signature test: a retrospective analysis

Aim MINDACT concluded that all breast cancer patients with a high clinical risk using a modified version of Adjuvant! Online need the 70-gene signature test (MammaPrint) to avoid adjuvant chemotherapy (aCT). As such aCT can safely be avoided in 71.5% (1093/1529) women with a high clinical risk grade 1-2 lesion. The aim of this study was to investigate distant recurrence free interval (DRFI) by use of aCT based on demographic and clinicopathological criteria only. Methods In this retrospective study we evaluated patients that were diagnosed in the Multidisciplinary Breast Center in the University Hospitals Leuven between 2000 and 2012. We assessed DRFI by use of aCT in our series of 942 consecutive grade 1-2 lesions with a high clinical risk (<71 years, grade 1, pN0, tumor size 3.1-5cm; <71 years, grade 1, pN1, tumor size 2.1-5cm; <71 years, grade 2, pN0, tumor size 2.1-5cm; <71 years, grade 2, pN1, any tumor size) as in MINDACT. Patients were estrogen receptor (ER) positive, human epidermal growth factor receptor2 (HER2) negative and received adjuvant endocrine therapy. Results In our center, aCT was used based on demographic and clinicopathological criteria only and 550 (58%) of high clinical risk patients did not receive aCT. The median follow-up was 8.2 years. The overall 5-year cumulative DRFI was 2.4% (95% CI, 1.5-3.2); this was 1.7% (95% CI, 0.9-3.1) in those who did not receive and 3.2% (95% CI, 1.8-5.4) amongst those who did receive aCT. Table 1 describes the patients who did not receive and who did receive aCT. Conclusion Omission of aCT based on clinicopathological results, in ‘MINDACT clinical high risk’, ER positive, grade 1-2 tumors, resulted in a low 5-year cumulative DRFI (1.7%). Clinicopathological factors may contribute to the most cost-effective use of gene expression profiles.status: publishe

Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial

Recent phase II and III clinical trials demonstrated anti-tumour activity of eribulin, a tubulin-interacting cytotoxic agent, in patients with metastatic soft tissue sarcoma (STS). In this exploratory study, we aimed to identify putative microRNA biomarkers that associate with eribulin sensitivity or resistance in STS.publisher: Elsevier articletitle: Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial journaltitle: European Journal of Cancer articlelink: http://dx.doi.org/10.1016/j.ejca.2016.12.018 content_type: article copyright: © 2017 Elsevier Ltd. All rights reserved.status: publishe

Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models

We evaluated the efficacy of CK6, a KIT monoclonal antibody, in a panel of human gastrointestinal stromal tumor (GIST) xenograft models. Nude mice were bilaterally transplanted with human GIST xenografts (four patient derived and two cell line derived), treated for 3 weeks, and grouped as follows: control (untreated); CK6 (40 mg/kg, 3× weekly); imatinib (50 mg/kg, twice daily); sunitinib (40 mg/kg, once daily); imatinib + CK6; sunitinib + CK6 (same doses and schedules as in the single-agent treatments). Tumor volume assessment, Western blot analysis, and histopathology were used for evaluation of efficacy. Statistical analysis was performed using Mann-Whitney U (MWU) and Wilcoxon matched-pairs tests. CK6 as a single agent only reduced tumor growth rate in the UZLX-GIST3 model (P = .053, MWU compared to control), while in none of the other GIST models an effect on tumor growth rate was observed. CK6 did not result in significant anti-proliferative or pro-apoptotic effects in any of the GIST models, and moreover, CK6 did not induce a remarkable inhibition of KIT activation. Furthermore, no synergistic effect of combining CK6 with tyrosine kinase inhibitors (TKIs) was observed. Conversely, in certain GIST xenografts, anti-tumor effects seemed to be inferior under combination treatment compared to single-agent TKI treatment. In the GIST xenografts tested, the anti-tumor efficacy of CK6 was limited. No synergy was observed on combination of CK6 with TKIs in these GIST models. Our findings highlight the importance of using relevant in vivo human tumor xenograft models in the preclinical assessment of drug combination strategies.status: publishe

Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumours: rationale and efficacy

Purpose: PI3K signalling pathway drives tumour cell proliferation and survival in gastrointestinal stromal tumour (GIST). We tested the in vivo efficacy of three PI3K inhibitors (PI3Kis) in patient-derived GIST xenograft models. Experimental Design: 168 nude mice were grafted with human GIST carrying diverse KIT genotypes and PTEN genomic status. Animals were dosed orally for two weeks as follows: control group (untreated); imatinib (IMA); PI3Ki (BKM120 - buparlisib, BEZ235 or BYL719) or combinations of IMA with a PI3Ki. Western blotting, histopathology and tumour volume evolution were used for the assessment of treatment efficacy. Furthermore, tumour regrowth was evaluated for three weeks after treatment cessation. Results: PI3Ki monotherapy showed a significant anti-tumour effect, reflected in tumour volume reduction or stabilization, inhibitory effects on mitotic activity and PI3K signalling inhibition. The IMA+PI3Ki combination remarkably improved the efficacy of either single agent treatment with more pronounced tumour volume reduction and enhanced pro-apoptotic effects over either single agent. Response to IMA+PI3Ki was found to depend on the KIT genotype and specific model-related molecular characteristics. Conclusions: IMA+PI3Ki has significant anti-tumour efficacy in GIST xenografts as compared to single agent treatment, resulting in more prominent tumour volume reduction and enhanced induction of apoptosis. Categorization of GIST based on KIT genotype and PI3K/PTEN genomic status combined with dose optimization is suggested for patient selection for clinical trials exploring such combinations.status: publishe

Breast cancer subtype and survival by parity and time since last birth

Pregnancy affects breast cancer risk but how it affects the subtype and prognosis remain controversial. We studied the effect of parity and time since last birth on breast cancer subtype and outcome.status: accepte

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients

Limited data are available on the prognostic performance of Adjuvant! Online (AOL) and Nottingham Prognostic Index (NPI) in young breast cancer patients.status: publishe

Triple receptor comparison between primary breast cancer and metachronous or synchronous liver metastasis

status: publishe